Meeting Coverage

Psych Congress

Psychiatry & Behavioral Health Learning Network

How Durable Are Responses to Novel Antidepressant Zuranolone in MDD?

SHORELINE trial found reduced depression symptoms even in those exiting study early

Psych Congress over a photo of the Ernest N. Morial Convention Center in New Orleans, Louisiana

Latest Psych Congress Meeting Coverage

Depression Treatment Failure Burdens Patients' Life and Wallets

Even mild cases tied to reduced quality of life and high medical costs, survey showed

September 21, 2022
Comorbidities May Stall Diagnosis of PTSD in the General Population

Analysis shows that many patients are treated for symptoms of the disorder before diagnosis

September 21, 2022
Low-Dose Cariprazine for MDD Tied to Anxiety Reduction

Potential add-on therapy also improved most individual depressive symptoms on MADRS

September 20, 2022
No Weird Dreams for Insomnia Patients Taking Lemborexant

Even at 10 mg, the sleep aid resulted in few abnormal dreams or nightmares

September 20, 2022
Trazodone Commonly Used Off-Label for Insomnia

Not much data to support efficacy or safety "as a surrogate hypnotic medication," researcher says

September 20, 2022
Rexulti Calms Alzheimer's Dementia-Related Agitation

But atypical antipsychotic disappoints in borderline personality disorder

September 19, 2022
Novel Combo for Schizophrenia Succeeds in Phase III Trial

Xanomeline-trospium has potential to be first-in-class therapy for schizophrenia if approved

September 19, 2022
Improvements in Treatment-Resistant Depression With Esketamine

Pooled data from randomized trials showed better scores on the PHQ-9 as well

November 2, 2021
Lemborexant Helps Insomniacs Catch More Z's

Even patients with history of depression had better sleep outcomes

November 2, 2021
Novel Oral Antidepressant Shows Rapid Symptom Improvement

Improvement with 50-mg zuranolone seen by day 3

November 2, 2021
Is Earlier Use of Long-Acting Injectable Drugs for Schizophrenia Better?

Early use linked to fewer inpatient stays and ER visits, study finds

November 1, 2021
Extended-Release Risperidone Injectable Staves Off Schizophrenia Relapse

Phase III RISE study found benefit with both once-monthly and bimonthly dose

November 1, 2021
COVID Doesn't Dampen LAI Antipsychotic Prescribing in Schizophrenia

Survey study shows no major changes in prescription trends in 2020

November 1, 2021
Migraine Drug Shows Benefit for Those With Comorbid Depression, Anxiety

Real-world study of fremanezumab found that patients were able to reduce antidepressant use

November 1, 2021